MDM2 Degrader as a Promising Therapeutic Strategy for Cancer Treatment

  • J Med Chem. 2025 Jul 10;68(13):13246-13248. doi: 10.1021/acs.jmedchem.5c01642.
Shiqi Wu  1  2 ,  Yungen Xu  1  2
Affiliations
  • 1. State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, PR China.
  • 2. Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, PR China.
PMID: 40568869 DOI: 10.1021/acs.jmedchem.5c01642
Abstract

MDM2, a key negative regulator of the tumor suppressor p53, has emerged as a compelling therapeutic target in human Cancer. This Viewpoint summarizes the discovery of a potent and orally bioavailable MDM2 Degrader that demonstrates unprecedented single dose antitumor efficacy. The compound holds substantial potential as a Cancer therapeutic and warrants thorough preclinical evaluation.

Products